Lajer Maria, Tarnow Lise, Jorsal Anders, Parving Hans-Henrik
Steno Diabetes Center, Niels Steensens Vej 2, DK-2820 Gentofte, Denmark.
Nephrol Dial Transplant. 2007 Nov;22(11):3235-9. doi: 10.1093/ndt/gfm360. Epub 2007 Jun 13.
Circulating N-terminal pro-brain natriuretic peptide (NT-proBNP) levels are elevated in patients with diabetic nephropathy and independently predict excess cardiovascular morbidity and mortality. Therefore, we investigated the association between two polymorphisms -381T/C and 1551G/A of the BNP gene, plasma NT-proBNP levels and mortality prognosis in 380 type 1 diabetic patients with and without diabetic nephropathy.
In a prospective observational follow-up study, 197 type 1 diabetic patients with diabetic nephropathy {121 men, age [mean (SD)] 41 +/- 9.5 years, duration of diabetes 28 +/- 8.0 years, glomerular filtration rate 67 +/- 28 ml/min/1.73 m2}, and a matched control group of 183 patients with longstanding type 1 diabetes and persistent normoalbuminuria (111 men, age 43 +/- 10.0 years, duration of diabetes 27 +/- 8.3 years) were followed for 12.6 (0.0-12.9) years. Plasma NT-proBNP concentration was determined by immunoassay at baseline. The BNP genotypes were determined by TaqMan chemistry based assays.
The two polymorphisms were in almost complete linkage disequilibrium (r2 = 0.883) and thus only the results of the -381T/C promoter polymorphism are shown. There was no significant difference between cases and controls in either genotype distributions (cases TT 32%, TC 53%, CC 15%; controls TT 28%, TC 52%, CC 20%) or allele frequencies (cases T/C 0.58/0.42; controls T/C 0.54/0.46) for the -381T/C polymorphism. Among the 164 normoalbuminuric patients without antihypertensive treatment and previous major cardiovascular disease (CVD), the -381T/C polymorphism was associated with circulating levels of NT-proBNP [median (interquartile range) 21 (5-32), 34 (12-67) and 32 (12-58) ng/l for TT, TC and CC, respectively (P = 0.041)] persisting after adjustment for covariates (P = 0.018). During follow-up, the -381T/C polymorphism did not predict all-cause or cardiovascular mortality among type 1 diabetic patients with or without diabetic nephropathy.
The BNP -381T/C and 1551G/A polymorphisms are associated with circulating levels of NT-proBNP but not with prevalent overt diabetic nephropathy. These polymorphisms do not predict all-cause or cardiovascular mortality in Caucasian type 1 diabetic patients with or without diabetic nephropathy.
糖尿病肾病患者循环血中N末端脑钠肽前体(NT-proBNP)水平升高,且可独立预测心血管疾病发病率和死亡率的增加。因此,我们研究了380例1型糖尿病伴或不伴糖尿病肾病患者中BNP基因的两种多态性(-381T/C和1551G/A)、血浆NT-proBNP水平与死亡预后之间的关系。
在一项前瞻性观察随访研究中,197例1型糖尿病肾病患者(121例男性,年龄[平均(标准差)]41±9.5岁,糖尿病病程28±8.0年,肾小球滤过率67±28ml/min/1.73m2),以及183例病程较长的1型糖尿病且持续正常白蛋白尿的匹配对照组患者(111例男性,年龄43±10.0岁,糖尿病病程27±8.3年)接受了12.6(0.0 - 12.9)年的随访。在基线时通过免疫测定法测定血浆NT-proBNP浓度。通过基于TaqMan化学的检测方法确定BNP基因的基因型。
这两种多态性几乎完全连锁不平衡(r2 = 0.883),因此仅显示-381T/C启动子多态性的结果。-381T/C多态性的基因型分布(病例组TT 32%,TC 53%,CC 15%;对照组TT 28%,TC 52%,CC 20%)或等位基因频率(病例组T/C 0.58/0.42;对照组T/C 0.54/0.46)在病例组和对照组之间均无显著差异。在164例未接受抗高血压治疗且无既往重大心血管疾病(CVD)的正常白蛋白尿患者中,-381T/C多态性与NT-proBNP的循环水平相关[TT、TC和CC基因型的中位数(四分位间距)分别为21(5 - 32)、34(12 - 67)和32(12 - 58)ng/L(P = 0.041)],在对协变量进行校正后仍然相关(P = 0.018)。在随访期间,-381T/C多态性不能预测1型糖尿病伴或不伴糖尿病肾病患者的全因死亡率或心血管死亡率。
BNP的-381T/C和1551G/A多态性与NT-proBNP的循环水平相关,但与显性糖尿病肾病的患病率无关。这些多态性不能预测白种人伴或不伴糖尿病肾病的1型糖尿病患者的全因死亡率或心血管死亡率。